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A simple, fast, and reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and valida-
ted for determining of a cannabinoid derivate, which displays potent antihyperalgesic activity, 1-naphthalenyl[4-(pentyloxy)-1-
naphthalenyl]methanone (CB13) into PLGA nanoparticles. Separation was achieved in a C18 column using a mobile phase con-
sisting of two solvents: solvent A, consisting of acetonitrile : water : acetic acid (75 : 23.7 : 1.3 v/v), and solvent B, consisting of ace-
tonitrile. An isocratic method (70 : 30 v/v), with a flow rate of 1.000 mL/min, and a diode array detector were used. The developed
method was precise, accurate, and linear over the concentration range of analysis with a limit of detection and a limit of quan-
tification of 0.5 and 1.25 µg/mL, respectively. The developed method was applied to the analysis of CB13 in nanoparticles samples
obtained by three different procedures (SEV, FF, and NPP) in terms of encapsulation efficiency and drug release. Nanoparticles
size and size distribution were also evaluated founding that NPP method presented the most lowest particle sizes with narrow-size
distribution (≈320 nm) and slightly negative zeta potential (≈ −25 mV) which presumes a suitable procedure for the synthesis of
PLGA-CB13 nanoparticles for oral administration.
1. Introduction
Nowadays, there is a special interest in the development of
new delivery systems able to allow an exhaustive control over
their physicochemical profiles. Nanotechnology is providing
a very useful technological tool in everything related to the
development of nanoparticle systems for actives. These
nanosystems have become of great interest because of their
capability to provide a wide range of products for several
administration routes able to exert a temporal and/or spatial
control in their release profiles [1–3]. According to the
objectives pursued with the use of the pretended nanopar-
ticle systems, there are several key elements that must be
considered because of their great influence over the products:
(i) the type of technology/method used in the production of
the nanoparticles, (ii) the physicochemical properties of the
molecules carried in the particles, and (iii) the specifically
properties of the polymers employed.
Related to the active molecules to be carried by these
nanosystems, one of the most important researches in
medicine is the treatment of pain. The pain reduces the
quality of life for millions of patients around the world and
drug treatments currently available, normally opioids and
anti-inflammatory drugs, are not effective in many clinical
situations. Cannabinoids have antinociceptive mechanisms
different from those used by the drugs currently employed,
providing a new line for the treatment of pain that is un-
responsive to drug treatments presently available [4]. Oral
administration is one of the routes most commonly used for
drug administration. However, it is not feasible when the
actives present unfavourable conditions: not adequate physi-
cochemical properties for intestinal absorption, stability
or solubility problems, and clear decrease in bioavailabil-
ity by first-pass hepatic effects, as the cannabinoids [4,
5].
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Figure 1: CB13 structural formula (C26H24O2).
A cannabinoid derivate was used in our study (Figure 1):
1-naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone
(CB13).
It is a CB1/CB2 dual agonist (selective activation of peri-
pheral cannabinoid CB1 receptors has the potential to be-
come a valuable therapy for chronic pain) which displays
potent antihyperalgesic activity in animal models and limited
brain penetration [6]. In the other hand, CB13 is a cannabi-
noid derivate highly lipophilic which belongs to class II
compounds, and as a consequence of its poor solubility and
dissolution in the gastrointestinal fluids, is incompletely ab-
sorbed [7].
During the last three decades, there has been continuous
interest in the use of biodegradable polymers for the deve-
lopment of nano- and micropolymeric delivery systems able
to improve drugs oral bioavailability, to control their thera-
peutic effect and to prolong it. Their encapsulation within
drug delivery systems allows to have a better pharmacoki-
netics pathway and to reduce drastically the frequency of in-
jection. In order to successfully develop these formulations,
poly(lactic-co-glycolic) acid (PLGA), one of the few polymers
approved by the Food and Drug Administration for human
clinical use, was chosen as biodegradable polymer [8–10].
PLGA polymers have shown to be biocompatible and they
degrade to toxicologically acceptable lactic and glycolic acids
[11].
In present work the production of different method for
CB13 encapsulation into PLGA nanoparticles was carried
out: (i) emulsion solvent evaporation method assisted by
ultrasounds (SEV-US) [12]; (ii) emulsion solvent evapora-
tion method assisted by Flow Focusing (SEV-FF) [13] (iii)
nanoprecipitation (NPP) [14]. Parameters such as particle
size, particles size distribution, surface charge, particle mor-
phology, drug loading, and in vitro release profile were eva-
luated.
The main goal of this study was the development and
validation of a simple and rapid HPLC method for quantifi-
cation of this molecule from possible pharmaceutical dosage
forms derived from nanoparticle systems. Several other
HPLC methods were also developed for the determination
of cannabinoids [15–18]. All of these methods, however,
are not employed for the determination of CB13 in a pos-
sible pharmaceutical dosage form and usually employed to
quantify illicit substances in biological fluids. Fischedick et al.
[18] developed a HPLC method for cannabinoids quan-
tification extracted from plant material. Mercolini et al. [16]
and Abbara et al. [17] developed HPLC methods for the
analysis of cannabinoids in urine and plasma after solid-
phase extraction.
In order to achieve this purpose, the analytical method
proposed has been used for investigating drug loading and
in vitro release profiles CB13 nanosystems produced by these
three different nanoencapsulation techniques.
2. Materials and Methods
2.1. Materials. 1-Naphthalenyl[4-(pentyloxy)-1-naphtha-
lenyl] methanone (CB 13) was obtained from Tocris (UK);
HPLC-grade acetonitrile, acetic acid, and ethyl acetate were
purchased from Panreac (Spain). Poly(lactic-co-glycolic)
acid block copolymer (PLGA 50 : 50) Resomer RG 502 (Mw:
12000; inherent viscosity: 0.24 dL/g) was obtained from
Boehringer Ingelheim (Germany). Surfactants employed,
Span 60, Mowiol 3-96 (PVA), and Pluronic F-68, were
obtained from Sigma-Aldrich.
Deionised and purified water using a Milli-Q system
(Millipore) was used for the standard solutions preparation.
All other reagents were of analytical grade.
2.2. RP-HPLC Method: Development and Validation
2.2.1. Equipment and Chromatographic Conditions. The chro-
matographic apparatus consisted of a Hitachi system man-
ager D-7000, equipped with a quaternary pump L-7100, a
diode array detector L-7455, an automatic injector L-7200,
and interface D-7000. For data collection and calculation,
HSM System Manager Software was used.
The chromatographic conditions [19–21] were a column
C18 (Waters Spherisorb 5 µm ODS2; 4.6×250 mm Analytical
Column, Ireland) and a mobile phase consisting of two
solvents: a mixture of acetonitrile : water : acetic acid (A)
(75 : 23.7 : 1.3 v/v) and acetonitrile (B). Eluent (70 : 30%
A : B) was pumped at 1.000 mL/min. The detection wave-
length UV was 230 nm and the injection volume was 10 µL.
The operating temperatures were maintained at room tem-
perature but the oven was heated at 40◦C to favour the
mobile phase flow through the column.
2.2.2. Preparation of Standard and Sample Solutions. Stan-
dard stock solution of CB13 at a concentration of 500 µg/mL
was prepared by weighting accurately 500 µg of CB13 and
dissolving it in 1 mL of acetonitrile. it was shaken vigorously
in a vortex until complete solubilization. Then, it was filtered
and injected into HPLC.
To carry out the sample solution, it was accurately
weighted around 5 mg of nanoparticles and added 1 mL of
acetonitrile. The samples were shaken vigorously in a vortex
(5 minutes) to promote the solubilization of cannabinoid
from the nanoparticles. BLAG from nanoparticles does not
interfere with analyte at the wavelength that CB13 is quan-
tified (see the complete validation study process). The
samples were filtered with 0.22 µm nylon-membrane filter
(Millipore, Barcelona) and injected directly into HPLC
[22].
The Scientific World Journal 3
2.2.3. Validation of the Method. The method was validated in
agreement with International Conference on Harmonization
(ICH) [23], using the following analytical parameters: linea-
rity, precision, accuracy, specificity, detection and quantifica-
tion limits, and robustness.
(i) Selectivity/specificity: was determined by comparing
nanoparticle carrier samples with and without CB13
(placebo).
In this work, the selectivity of the method was evaluated
in three different samples (solution of placebo, solvent, and
standard solution of CB13 (500 µg/mL)), which were injected
to check their specificity.
Moreover, degradation studies, where the standard solu-
tions of the drug were subjected to different degrees of stress
(ICH), were carried out: temperature, light, and pH.
CB13 is not soluble in acidic or basic aqueous solutions,
so that, first, it was solubilized in its normal solvent (aceto-
nitrile) and then, it was acidified or alkalinized with a little
amount of acid or base and it was incubated for 5 hours.
Later, the solutions were neutralized with basic or acid solu-
tions and completed to a final volume with acetonitrile; for
heat-forced degradation, a standard solution of CB13 was
incubated 24 h in 60◦C (oven); for sun light forced degra-
dation, a standard solution of CB13 was exposed 24 h to sun
light.
After the stress assay, the samples were analyzed by HPLC
as shown in the chromatographic conditions.
(ii) Precision: was assessed by testing the repeatability of
three different standard solutions 10 times in the
same day (intra-day) and by intermediate precision
analyzing the same three standard solutions on dif-
ferent days (n = 10) (inter-day).
(iii) Accuracy: was tested by mean percentage recoveries of
three samples of CB13 at five different concentrations
precisely prepared and by determination of the rela-
tive standard deviation (RSD). Specificity was deter-
mined by comparing nanoparticulate carrier samples
with and without CB13 (placebo).
It was studied the concentration levels of 50%, 75%, 100%,
125%, and 150%, where a known amount of the active was
added to a determined amount of placebo solution to obtain
drug concentrations of 250, 375, 500, 625, and 750 µg/mL,
respectively. The amount of CB13 recovered in relation to the
added amount (recovery percent), was calculated [23].
(iv) Linearity: a linear relationship should be evaluated
across the range of the analytical procedure. It was
demonstrated directly on the drug substance (by
dilution of a standard stock solution).
Linearity should be evaluated by visual inspection of a
plot of signals as a function of analyte concentration or
content. If there is a linear relationship, test results should be
evaluated by appropriate statistical methods. For the estab-
lishment of linearity, a minimum of 5 concentrations is re-
commended [24].
This study was performed by evaluating the system and
method linearity. For the system linearity, standard solutions
of CB13 at five concentrations levels, from 50% at 150% of
the target analyte concentration, were calculated. Each level
of concentration was prepared in triplicate. The experimen-
tal results were graphically plotted, obtaining a calibration
curve and carrying out the corresponding statistical study.
For the method linearity, the procedure was the same
as that of system linearity, but the sample was a solution
containing the PLGA nanoparticles (placebo) and adding an
increased amount of CB13, dissolved in the medium. The
results were treated the same way for the system linearity
[20].
2.2.4. Limit of Detection (LOD) and Quantification (LOQ).
LOD and LOQ tests for the procedure were performed on
samples containing progressively more dilute concentrations
of analyte. Afterwards, the concentrations versus the RSD
obtained for area from each of the concentrations were plot-
ted in order to determine LOD and LOQ [25].
2.2.5. Robustness. The robustness/ruggedness of an analyti-
cal procedure is a measure of its capacity to remain unaffec-
ted by small but deliberate variations in method parameters
and provides an indication of its reliability during normal
usage [23] according to the application.
In the case of liquid chromatography, examples of these
variations are changes in pH of the mobile phase (±0.2
units); variation in mobile phase composition (±8% of each
solvent); oven temperature (±2◦C) and flow rate (±0.1 mL/
min) [26].
The pH adjustment procedure was carried out in agree-
ment with International Conference on Harmonization
(ICH) [24], using solutions of hydrochloric acid and sodium
hydroxide.
2.3. Preparation of CB13-Loaded Nanoparticles. In present
work three different methods for CB13 nanoparticles syn-
thesis were assayed. CB13 is a cannabinoid derivate highly
lipophilic which belongs to class II compounds (low sol-
ubility and a high permeability) of the Biopharmaceutics
Classification System (BCS), showing low water solubility
(∼0.001–0.002 mg/mL). As a consequence of its poor sol-
ubility and dissolution in the gastrointestinal fluids, this
compound is incompletely absorbed [7]. Although there are
diverse strategies (use of cosolvents, salt formation, com-
plexes with cyclodextrins, etc.) to solve this problem, various
nanotechnology-based drug delivery systems have emerged
to increase the bioavailability of numerous drugs that are
poorly soluble in water [27, 28]. So, to improve CB13 oral
bioavailability, it was incorporated into PLGA nanoparticles
by three methods.
Emulsion-Solvent Evaporation Method Assisted by Ultrasounds
(SEV-US) [29]. An o/w emulsion was prepared to obtain
solid PLGA nanoparticles. As oil phase a cosolution of canna-
binoid (0.1 mL, 0.5% w/v) and PLGA (1 mL, 10% w/v) in
ethyl acetate (EA) was prepared. This solution was added
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dropwise to a 0.3% (w/v) PVA solution under sonication.
The recently prepared emulsion was diluted by adding 20 mL
of a 2% (w/v) PVA solution, stirred at r.t. for 4 h. After this,
particles were collected by centrifugation (10000 rpm, 4◦C,
and 20 min) and washed three times with distilled water.
Finally, particles were freezing dried (Cryodos, Telstar) and
stored at 4◦C.
Emulsion-Solvent Evaporation Method Assisted by Flow-Focus-
ing (SEV-FF) [30]. In this case, to prepare the o/w emulsion,
a simple Flow Focusing nozzle (Ingeniatrics Tecnologı́as,
Spain) was used. As oil phase (focused fluid), a cosolution of
cannabinoid (0.1 mL, 0.5% w/v) and PLGA (1 mL, 10% w/v)
in ethyl acetate (EA) was injected at 0.2 mL/h. As aqueous
phase (focusing fluid), a distilled water was injected at 2 mL/
min. The o/w emulsion is collected inside a PVA (0.5% w/v)
bath under magnetic agitation at r.t. for 4 h. After this, par-
ticles were manipulated as previously described [31].
Nanoprecipitation (NPP) [32]. Briefly, a co-solution of PLGA
(1.5% w/v), CB13 (0.25% w/v), and Span 60 (0.5% w/v)
in acetone was dropped onto a Pluronic F68 (0.5% w/v) solu-
tion at 5 mL/min flow rate under magnetic stirring. After
acetone evaporation, NPs suspension was filtered by 1 µm
pore size filter (Millipore). After this, particles were manipu-
lated as previously described.
2.4. Characterization Methods. The mean diameter and size
distribution of CB13 loaded-PLGA nanoparticles were mea-
sured at 25.0± 0.5◦C by a laser scattering technique based on
Mie theory (Partica LA-950V2, Horiba, Japan).
Nanoparticles surface charge was determined by zeta
potential (ZP) measurements. The ZP of the particles was
determined by laser Doppler (Zetamaster 300, Malvern Ins-
truments Ltd, Malvern, UK). ZP measurements were carried
out in triplicate after washing the nanoparticles with distilled
water at r.t.
The shape and morphology characteristics of the nano-
particles were determined by scanning electron microscopy
(SEM) (Philips XL-30, USA) after coating lyophilised sam-
ples with a gold thin film.
2.5. Evaluation of Drug Content from PLGA Nanoparticles.
CB13 content of nanoparticles was assessed directly by HPLC
from the extraction of the drug of nanoparticles. The drug
content was expressed as encapsulation efficiency percentage
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Figure 2: Chromatograms of solvent (•) placebo () and standard
solution of CB13 ().
2.6. In Vitro Release Profile. To establish the CB13 release
profile from nanoparticles at simulated gastric and intestinal
pH, nanoparticles were suspended in USP XXVI HCl buffer
pH 1.2 or USP XXVI HCl buffer pH 6.8 at 37◦C and stir-
red mechanically (100 rpm) during the release experiments
(Unitronic OR, Selecta, Spain). Aliquots (500 µL) were with-
drawn at fixed time intervals and filtered upon centrifugation
at 8000 rpm. The filtered sample (Millex GV) (10 µL) was
injected into the HPLC apparatus for the evaluation of CB13.
3. Results
3.1. HPLC Method Development. The chromatographic con-
ditions were optimized for the determination of CB13
within a suitable analysis time (20 min) and peak (isolated,
symmetric, etc.).
With regard to the mobile phase, an HPLC method for
cannabinoids was described [19], in which methanol, water
and acetic acid (75 : 23.7 : 1.3, v/v/v) were used as the mobile
phase. However, the time retention was too longer and a
major proportion of methanol could decrease the CB13
retention time. So, the following mobile phase was a mix
70 : 30 (v/v) of two solutions: the solution given above and
a methanol solution. Later, methanol was changed to aceto-
nitrile because the first produced gas in the HPLC system and
the peak moved to different retention times.
3.2. Validation Study
3.2.1. Selectivity/Specificity. The specificity of the method
was verified by comparing the chromatograms of standard
CB13 and those of potential interfering formulation compo-
nents. The chromatograms obtained in HPLC for the placebo
and the solvent do not show any peak with a similar retention
time to that of the CB13 (10.88 min± 10%) (Figure 2). So, it
was observed the absence of interferences of the excipients
for pharmaceutical preparation, because none of the peaks
appears at the same retention time than CB13 peak. Then,
it was concluded that the developed method is selective in
relation to the excipients of the final preparation.
Also, tests were performed under three stress conditions
(temperature, sun light, and pH) in order to detect the oc-
currence of possible interfering peaks resulting from degra-
dation of CB13. Furthermore, these tests are regarded as
helpful tools in establishing degradation pathways and the
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Table 1: Results of recovery (%) and RSD (%) for CB13 from stan-
dard solutions (n = 6) (level I: 250 µg/mL; level II: 375 µg/mL; level
III: 500 µg/mL; level IV: 625 µg/mL; level V: 750 µg/mL).
Level Theoretical mean (µg) Recovery (%) R.S.D
I 250.46 101.04 0.54
II 375.48 100.50 1.06
III 500.40 101.47 0.36
IV 625.43 98.86 0.68
V 750.46 101.15 0.46
inherent stability of the molecule and help invalidating the
power of the proposed method for studying the stability of
CB13 [26]. According to the areas obtained, the mean degra-
dation value obtained was 7.50%; it can be concluded that
CB13 is stable in these conditions. Therefore, the method is
selective and suitable for routine work [20].
3.2.2. Precision. Precision expresses the importance that
random errors have on the method performance and can
be expressed at different levels. In the case of the developed
method, precision has been validated for various repeatabil-
ity studies.
Instrumental Precision. The repeatability of the instrumental
system was evaluated with replicate injections (n = 6) of a
single standard preparation (500 µg/mL). In this case an ave-
rage area of 7895081.83 ± 64499.17 (RSD = 0.82) and an
average retention time of 10.86 ± 0.04 min (RSD = 0.34)
were obtained. These results indicatedthat the analytical of
the instrumental system is in optimum conditions, because
the acceptance criterion in analysis of pharmaceutics formu-
lations establishes the limit RSD in 1.5% [23, 24, 33].
Method Repeatability. It was determined by using the results
obtained in the accuracy tests (in three concentrations
levels: low level (50%), middle level (100%), and high level
(150%)). The RSD was measured and the values are showed
in Table 1. To summarize, RSDs for the six recovery values
for levels I, III, and V of the accuracy test are less than 2.0%
(acceptance criteria) [27, 29, 33]. For this reason, this study
was considered validated.
Intermediate Precision or Reproducibility of Analytical Meth-
od. It was performed on samples containing standard solu-
tions of CB13 by different analysts and different days. The
result obtained for the average area was 8097677.88 ±
132650.17 with an RSD value of 1.64. The RSD value of
analysis performed was less than 2%, which demonstrates
that the method is reproducible, because the introduced
variations in the test have no influence on the experimental
results [27, 29, 33].
3.2.3. Accuracy. Table 1 shows the results for the six recov-
ery percents obtained for the concentration interval 250–
750 µg/mL. The individual values are between 98.04% and















Figure 3: LOQ-LOD obtaining by plotting the area RSD (%) versus
the CB13 concentrations.
According to the obtained results, it would not be neces-
sary to make any additional statistical test, because ICH for
pharmaceutical formulations establishes the recovery percent
in accuracy test which must be between 98% and 102%,
which is equivalent to ±2.0% of the relative error [27, 33].
3.2.4. Linearity. It was studied in the concentration range of
250–750 µg/mL by calculating the regression equation and
the correlation coefficient (R2). The equation of the regres-
sion lineal obtained corresponds to the following expression:
Y = 16898∗ X + 317039 (n = 6; R2 = 0.9983), (2)
where Y is the peak area and X is the CB13 concentration
(µg/mL).
For the method linearity, the concentration range was the
same as that for the system linearity and the equation of the
regression line obtained was Y = 14303.52 ∗ X + 316730.81
with a correlation coefficient R2 = 0.9952.
For these studies it was carried out a statistical analysis
to ensure a good linearity of the method (ANOVA). The F
test statistic (F) and its corresponding P value (significance
F) certainly indicate an overall goodness of fit for the model
(P = 2.45·10−11 for the system linearity and P = 1.89·10−14
for the method linearity).
3.2.5. Limit of Detection (LOD) and Limit of Quantification
(LOQ). The lowest concentration at which an analyte can be
detected (LOD) or quantified with acceptable precision and
accuracy (LOQ) was determined by plotting the area RSD
(%) versus analyte concentration (Figure 3) [34].
The CB13 concentrations used for this study were lower
than the end region of the range of the proposed method
(0.5, 1.25, 2.5, 4, 5, 10, 20, and 35 µg/mL). The maximum
concentration in this study (35 µg/mL) corresponded to a
detector signal of around 5% of the minimum area included
in the calibration curve.
The first point which does not fulfill the minimum RSD
that obeys preset requirements to study reproducibility (2%)
corresponds to the LOD. The LOD value was found to be
0.5 µg/mL. The first point which fits into this specified value
corresponds to the LOQ, being found at 1.25 µg/mL [35].
The results obtained in this study suggested the em-
ployment of a new calibration curve in lower regions of
concentrations to quantify minor amounts of CB13; this
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Table 2: Robustness test of proposed method in terms of recovery (%) and RSD (%) for 500 µg/mL CB13 standard (n = 3) (MP: mobile
phase).
Changes to original method Theoretical mean (µg) Peak area Experimental (µg) Recovery (%) RSD
MP proportion (A : B) 65 : 35 500.60 7787498.33 502.83 100.45 0.98
MP proportion (A : B) 75 : 25 500.53 7826118.67 507.95 101.48 1.11
MP pH= 2.70 500.43 7821110.33 507.29 101.37 0.84
MP pH= 3.10 500.50 7811209 505.98 101.09 0.74
Oven temperature −2◦C 500.46 7814675 506.44 101.19 1.35
Oven temperature +2◦C 500.30 7832734 508.83 101.71 1.04
Flow rate −0.1 mL/min 500.36 7835018,67 509.14 101.75 0.84
Flow rate +0.1 mL/min 500.50 7809528 505.75 101.08 0.87
Table 3: Optimized formulations: influence of production method (n = 6) (initial amount of CB13 (6% w/w).
Method Dmean ± SD (nm) ZP (mV) EE± SD (%) Drug loading (%w/w)
SEV-US 420.30± 215.43 −29.5± 1.9 69.54± 0.34 4.172± 0.45
SEV-FF 990.61± 10.90 −25.6± 3.2 92.87± 0.96 5.572± 0.39
NPP 320.73± 108.02 −24.5± 2.3 85.69± 0.940 5.141± 0.67
calibration curve will be useful in some tests such as in vitro
release studies. For this reason, a new calibration curve was
established in the range from 2.5 to 750 µg/mL: Y = 17268∗
X + 190397 (R2 = 0, 9900) (F = 583.78; P = 3.25 · 10−3).
3.2.6. Robustness. The evaluation of robustness was based on
the percentage recovery and RSD values obtained for differ-
ent changes in the method analysis and using CB13 solutions
at different pH, mobile phase proportion, and temperature
and flow rate. Table 2 shows the recovery percents and the
RSD of each changed parameter studied: oven temperature
(±2◦C); flow rate (±0.100 mL/min); mobile phase propor-
tion (A : B 75 : 25 and A : B 65 : 35) and mobile phase pH
(±0.2 units). As is shown in the table, the individual recovery
percents obtained in all parameters studied are between
99.33% and 102.87% and the RSD of each one is less than
2%. Thus, the method showed to be robust concerning small
but expectable variations of the analysis method [36].
3.3. Nanoparticles Characterization and Application of the
HPLC Method. The proposed method was applied to study
CB13 association with nanoparticulate PLGA carriers pro-
duced by three different pathways: SEV-US, SEV-FF, and
NPP. These methods are potentially suitable for CB13 encap-
sulation, a highly lipophilic drug.
A brief comparative study of nanoparticles production
procedures was carried out. The aim of this study was to esta-
blish the most appropriate process for CB13 encapsulation
into PLGA nanoparticles in terms of particle size, particle size
distribution, drug content as well as in vitro release profile.
For this purpose an RP-HPLC method has been developed
and validated.
Because the preparation and characterization of well-
defined sizes of particles remain a challenge, we carried out
a brief comparative study gauged by comparing PLGA parti-
cles fabricated using two of the main traditional methods for
lipophilic drugs (SEV-US and NPP) and by SEV-FF which
has been demonstrated be able to produce highly uniform
particles [29, 37–39]. Results obtained are summarized in
Table 3. As it can be seen, particle size was strongly affected by
the synthesis procedure. In SEV-US and SEV-FF it is needed
a preemulsion formation. The main difference in these two
methods is the energy, applies to form the emulsion. In
SEV-US, high energy is applied as ultrasound. This is one
of the most employed methods to produce PLGA nano-
particles; the method is economic, simple and provides high
performance; nevertheless it presents low control on particle
size distribution [38]. For the optimized formulation using
this method, particles 420 nm in diameter with VCs higher
than 55% were obtained.
In SEV-FF the energy contribution is obtained by liquid
pressure (or gas pressure). In this case, a jet is formed; this
jet breaks up into drops as a result of a hydrodynamic ins-
tability due to tensile strength forces [40]. In general, the
main advantages of FF include, among others, (i) particles
production occurs under gentle conditions, which makes it
suitable for labile compound encapsulation, (ii) it is able to
predict the final particle size controlling the particle size
distribution, and (iii) it is possible to scale up the rate pro-
duction when multiple parallel devices are operated [40]. In
present work, particles less than one micrometer in diameter
were obtained with a very narrow particle size distribution
(CV ∼ 10%).
In NPP, NPs formation occurs also under mild con-
ditions, which does not require extended shearing/stirring
rates, sonication, or very high temperatures. By adding the
polymer solution into an aqueous solution a displacement
of solvent takes place which is translated into polymer pre-
cipitation. NPP appears to be governed by the Marangoni
effect, wherein movement in an interface is caused by lon-
gitudinal variations of interfacial tension. In such a case, pre-
cipitation is driven by (i) solute transfer out of the phase of
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Figure 4: SEM micrographs of CB13-PLGA nanoparticles obtained by three different procedures: (a) SEV-Us, (b) SEV-FF, and (c) NPP. The




























Figure 5: Drug release profile from nanoparticles prepared by three
different methods: NPP, SEV-US, and SEV-FF.
higher viscosity, which is influenced by high concentration
gradients at the interface and (ii) by interfacial tension [41].
Under optimized conditions (polymer concentration, sur-
factant concentration, addition rate, etc.) it was possible to
obtain particles in the nanoscale range with almost narrow
particle size distribution (320.73± 108.02 nm).
In Figure 4 are shown, as examples, SEM micrographs for
CB13-PLGA nanoparticles obtained by each method assayed.
As it can be seen, spherical and smooth particles were
obtained in all cases with narrow-size distribution for SEV-
FF and NPP methods. In SEV-FF method especially highly
uniform particles were obtained. For instance, in SEV-US
method, wide size distribution was obtained and the pre-
sence of aggregates was also appreciated.
Related to nanoparticles surface charge, zeta potential
values were measured (Malvern Zetasizer 3000, UK). In all
cases, nanoparticles presented zeta potential values slightly
negative (around −25 mV) due to chemical structure of
PLGA; no influence of nanoparticle synthesis pathway was
observed. These results guarantee the stability of nanoparti-
cles in suspension and facilities nanoparticles oral absorption
across intestinal membrane [42].
3.4. Drug Content in Nanoparticles. The drug loading of the
NPs is an important factor in their formulations since high
loading implies fewer amounts of the NPs are needed for a
given dose of the treatment. The CB13 loading (% w/w) as
well as the encapsulation efficiency percentage (EE%) was
tested by RP-HPLC.
In terms of entrapment efficiency (EE%), high values
were achieved for all NPs prepared due to the poor solubility
of CB13 in the external aqueous phase. In all cases EE was
superior to 60%.
These results indicated a high degree of encapsulation
of CB13 into PLGA nanoparticles. Similar results were ob-
tained for lipophilic [13] and hydrophilic [29] molecules in
previous works.
3.5. In Vitro Release Profiles. The representative CB13 in vitro
release profiles from nanoparticles obtained by three differ-
ent methods in gastric and intestinal pH-simulated condi-
tions are illustrated in Figure 5.
This study is used to demonstrate that the developed and
validated HPLC method is adequate to characterization of
CB13 nanoparticles. In fact, the HPLC method developed
is useful to study possible differences in the dissolution
behaviour of multiparticulate systems studied
As it can be seen, there is an inverse relationship between
release rate and NPs particle size. This has been explained by
other authors such as Berkland et al. [43]: they verified that
large microspheres degrade more quickly than small mic-
rospheres, probably because of an increased accumulation
of the acidic products of polymer hydrolysis in large mic-
rospheres. Particle size is determined by the synthesis pro-
cedure (SEV-FF> SEV-US>NPP).
After 2 h of assay, hydrolysis degradation products of
CB13 were not detected and only a well-defined peak ap-
peared on chromatogram, indicating that developed PLGA
nanocarrier allows retain CB13 in its structure, so to achieve
the stated objectives.
4. Conclusions
The proposed HPLC method has been evaluated over the
selectivity/specificity, precision, accuracy, linearity, range,
limit of detection, limit of quantification, and robustness and
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proved to be convenient and effective for the quality control
of CB13 in PLGA nanoparticles. It has been proved that it
was selective, linear between 50% and 150% of the work con-
centration (500 µg/mL) for CB13, with a correlation coeffi-
cient higher than 0.998, exact and precise. Limits of detection
and quantification for the drug were 0.5 and 1.25 µg/mL,
respectively, and these values are under the lowest expected
concentrations in the samples. Moreover, the method has
proved that it was robust.
The HPLC method was applied for CB13 evaluation in
PLGA nanoparticles obtained by three different pathways. It
was observed that SEV-FF method produced highly uniform
particle size although the minimum particle size obtained
was in the limit for an efficient oral administration. In NPP,
particles obtained presented high drug content with a reaso-
nable EE% and an acceptable particle size and particle size
distribution. So, we consider this last synthesis method as the
most suitable for CB13-PLGA nanoparticles for oral admi-
nistration in neuropathic pain treatment.
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